查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967723

特種藥品市場－全球產業規模、佔有率、趨勢、機會和預測：按應用、分銷管道、地區和競爭格局分類，2021-2031年

Specialty Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球特種藥品市場預計將從 2025 年的 1,293.4 億美元成長到 2031 年的 1,945.4 億美元，複合年成長率為 7.04%。

該領域涵蓋高以金額為準、複雜的藥品，例如生物製藥和孤兒藥，專注於治療慢性病、罕見疾病和危及生命的疾病，包括癌症、自體免疫疾病和嚴重病毒感染疾病。推動該領域成長的關鍵因素包括全球慢性病盛行率的不斷上升、人口老化對先進醫療服務的需求日益成長，以及治療分子研發的快速發展。國際藥品製造商協會聯合會（IFPMA）在2024年發布的報告顯示，上年度全球共推出了69種新的活性成分，體現了該產業對創新的承諾。

市場概覽
預測期 2027-2031
市場規模：2025年 1293.4億美元
市場規模：2031年 1945.4億美元
複合年成長率：2026-2031年 7.04%
成長最快的細分市場 醫院基地
最大的市場 北美洲

然而，這些治療方法費用的飆升是市場成長的主要障礙，加劇了醫療預算的壓力，並催生了嚴格的報銷通訊協定。衛生部門和支付方正日益採用嚴格的基於價值的定價模式和成本控制策略，這給患者就醫設置了障礙。這種經濟壓力迫使製造商必須證明其產品具有卓越的臨床療效才能獲得保險覆蓋，這也使得在價格敏感地區進入市場變得更加複雜。

市場促進因素

生物製藥和基因療法的技術進步正在改變全球專科藥物市場，為以往無法治癒的遺傳性疾病和罕見疾病提供了根治性選擇。這種變革，尤其是在細胞和基因療法領域，其特點是從症狀治療轉向緩解疾病療法，後者因其臨床療效和複雜性而具有巨大的市場價值。這些先進療法的快速監管核准是這一趨勢的基石，使研發公司能夠成功滿足罕見疾病領域巨大的未滿足需求。例如，再生醫學聯盟於2024年1月發布的《行業趨勢簡報》報告稱，2023年有五種用於治療罕見疾病的新型基因療法核准，其中包括鐮狀細胞貧血症和A型血友病，這證實了該領域有能力創造高附加價值創新，從而帶來可觀的收入。

同時，複雜慢性疾病（尤其是自體免疫疾病和腫瘤）發生率的上升，是推動治療需求持續成長的主要動力。隨著全球人口結構的變化和診斷技術的進步，我們需要穩定的專業藥物供應來應對這些危及生命的疾病所帶來的沉重負擔。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告，預計2024年美國新增癌症病例將首次超過200萬例。日益加重的疾病負擔迫使醫療系統增加對專科藥物的資源投入，從而推高了市場總值。根據美國系統藥師協會於2024年7月發布的《處方藥支出國家趨勢與預測》，2023年美國藥品總支出成長13.6%，達到7,225億美元。這一成長主要由腫瘤藥物和專科藥物的使用增加所驅動。

市場挑戰

專科治療費用的不斷上漲導致了嚴格的報銷政策和患者用藥限制，這對市場成長造成了重大障礙。隨著製藥商推出高價孤兒藥和生物製藥，政府機構和醫療保險公司優先考慮成本控制策略以應對預算限制。這些機構採用嚴格的基於價值的定價框架，並要求在核准保險覆蓋前提供強力的經濟可行性和臨床優勢證據。因此，監管核准與實際市場分銷之間出現了差距，有效地縮小了目標患者群體，並延緩了製藥公司的產生收入。

這種經濟摩擦在一些關鍵市場尤為明顯，這些市場的保險覆蓋決策遠遠落後於監管核准。根據歐洲製藥工業協會聯合會（EFPIA）2024年的數據，歐盟患者獲得新核准藥物的平均等待時間長達578天，而僅有29%的中央認證核可藥能夠完全納入公共醫保報銷範圍。如此漫長的等待時間和保險覆蓋範圍的限制直接阻礙了已通過核准專科藥物的商業性化應用，迫使生產商在複雜的市場進入環境中艱難前行，並阻礙了整個行業的擴張。

市場趨勢

機器學習和人工智慧的快速應用正在從根本上改變全球特種製藥市場，加速藥物發現並最佳化臨床開發流程。人工智慧平台能夠快速識別新的治療標靶並預測分子間相互作用，從而顯著減少將複雜生物製藥推向市場所需的資金和時間。為了因應這一趨勢，各公司正加大大規模投資力度，利用運算能力來獲取競爭優勢。例如，在2025年10月一篇題為《賽諾菲創投投資6.25億美元用於人工智慧》的報導中，《全球企業創投》報道稱，賽諾菲創投將其管理資本增至14億美元，其中新增6.25億美元專門用於資助將人工智慧應用於藥物發現的Start-Ups。

同時，替代生物製藥和生物相似藥的興起正在重塑市場動態，引入的內在競爭使患者更容易獲得高價值的治療。隨著主要生物製藥的專利保護期到期，價格合理的生物相似藥的出現消除了經濟障礙，並為醫療保健系統提供了一種切實可行的方法來遏制藥品成本的飆升。這種轉變得益於不斷提高的採用率和顯著的經濟效益。正如《連鎖藥品評論》（Chain Drug Review）2025年9月刊援引美國學名藥協會（AAM）的報告《2024年學名藥和生物類似藥節省4670億美元》所指出的，生物類似藥行業已累計為醫療保健系統和患者節省了562億美元，凸顯了其在負擔專科治療經濟方面的重要性減輕。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球特種藥品市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用領域（腫瘤學、多發性硬化症、發炎性疾病、感染疾病等）
    • 分銷通路（線下、線上）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美特用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲特用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區特用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲特用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲特用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球特種藥品市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19763

The Global Specialty Pharmaceuticals Market is projected to expand from USD 129.34 Billion in 2025 to USD 194.54 Billion by 2031, registering a CAGR of 7.04%. This sector comprises high-value, complex medications, such as biologics and orphan drugs, tailored for chronic, rare, or life-threatening diseases like cancer, autoimmune disorders, and severe viral infections. Growth is primarily driven by the increasing global incidence of chronic conditions, an aging demographic requiring advanced care, and rapid advancements in therapeutic molecule development. Highlighting the industry's dedication to innovation, the International Federation of Pharmaceutical Manufacturers & Associations reported in 2024 that 69 novel active substances were introduced globally in the previous year.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 129.34 Billion
Market Size 2031USD 194.54 Billion
CAGR 2026-20317.04%
Fastest Growing SegmentHospital-based
Largest MarketNorth America

However, the escalating expense of these therapies poses a significant obstacle to market growth, straining healthcare budgets and necessitating strict reimbursement protocols. Health authorities and payers are increasingly adopting rigorous value-based pricing models and cost-control strategies, creating hurdles for patient access. This economic pressure forces manufacturers to prove exceptional clinical outcomes to ensure coverage, thereby complicating market entry in price-sensitive regions.

Market Driver

Technological advancements in biologics and gene therapies are transforming the Global Specialty Pharmaceuticals Market by providing curative options for previously untreatable genetic and rare disorders. This evolution is defined by a transition from symptomatic treatment to disease-modifying solutions, especially within cell and gene therapies, which hold substantial market value due to their clinical effectiveness and complexity. The rapid regulatory endorsement of these advanced treatments underscores this trend, with developers successfully addressing orphan indications that have high unmet needs. For example, the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2024 noted that five new gene therapies for rare conditions, including sickle cell disease and hemophilia A, were approved in 2023, confirming the sector's ability to produce high-value innovations that generate significant revenue.

Simultaneously, the rising incidence of complex chronic diseases, especially autoimmune disorders and oncology, serves as a major driver for ongoing therapeutic demand. As global demographics evolve and diagnostic methods advance, the weight of these life-threatening illnesses requires a steady stream of specialized pharmacotherapies. The American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projects that new cancer diagnoses in the United States will surpass 2 million for the first time in 2024. This escalating disease burden compels healthcare systems to dedicate more resources to specialty medicines, thereby boosting overall market value. According to the American Society of Health-System Pharmacists' 'National Trends in Prescription Drug Expenditures and Projections for 2024' released in July 2024, total U.S. pharmaceutical spending rose by 13.6% in 2023 to $722.5 billion, driven significantly by the use of oncology and specialty drugs.

Market Challenge

The rising costs associated with specialty therapies create a significant obstacle to market growth by instigating strict reimbursement policies and limiting patient access. As manufacturers launch high-value orphan drugs and biologics, government authorities and healthcare payers are prioritizing cost-containment strategies to handle restricted budgets. These organizations are rigorously applying value-based pricing frameworks, demanding strong evidence of economic justification and clinical superiority prior to approving coverage. As a result, the disparity between regulatory authorization and actual market availability is increasing, which effectively reduces the addressable patient base and postpones revenue generation for pharmaceutical firms.

This economic friction is clearly observed in major markets where coverage determinations lag significantly behind regulatory approvals. Data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) in 2024 indicates that the average wait time for patients in the European Union to access newly approved medications reached 578 days, with only 29% of centrally approved drugs being fully accessible through public reimbursement systems. Such extended delays and restricted coverage directly hinder the commercial adoption of approved specialty products, compelling manufacturers to maneuver through complicated market access environments that constrain the sector's general expansion.

Market Trends

The rapid incorporation of Machine Learning and Artificial Intelligence is fundamentally transforming the Global Specialty Pharmaceuticals Market by accelerating drug discovery and refining clinical development processes. AI-powered platforms facilitate the quick identification of new therapeutic targets and predict molecular interactions, drastically cutting the capital and time needed to launch complex biologics. This trend is prompting significant strategic investments as firms aim to utilize computational capabilities for a competitive edge. For instance, Global Corporate Venturing reported in October 2025 in the article 'Sanofi Ventures bets on AI with $625m cash influx' that Sanofi Ventures raised its managed capital to $1.4 billion by adding $625 million specifically to fund startups applying artificial intelligence to drug discovery.

At the same time, the rise of interchangeable biologics and biosimilars is restructuring market dynamics by introducing essential competition that improves patient access to high-value treatments. As patent exclusivity for major biologics ends, the arrival of affordable biosimilars is breaking down financial obstacles and providing healthcare systems with a viable method to control escalating drug costs. This transition is supported by increasing adoption rates and significant economic benefits. As noted by Chain Drug Review in September 2025, referencing an AAM report titled '$467B saved by generics and biosimilars in 2024', the biosimilars sector has delivered a cumulative $56.2 billion in savings for the healthcare system and patients, confirming its importance in alleviating the financial strain of specialty therapies.

Key Market Players

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

Report Scope

In this report, the Global Specialty Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specialty Pharmaceuticals Market, By Application

  • Oncology
  • Multiple sclerosis
  • Inflammatory conditions
  • Infectious diseases
  • Others

Specialty Pharmaceuticals Market, By Distribution Channel

  • Offline
  • Online

Specialty Pharmaceuticals Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specialty Pharmaceuticals Market.

Available Customizations:

Global Specialty Pharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specialty Pharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Oncology, Multiple sclerosis, Inflammatory conditions, Infectious diseases, Others)
    • 5.2.2. By Distribution Channel (Offline, Online)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Specialty Pharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Specialty Pharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Specialty Pharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Specialty Pharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Specialty Pharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Specialty Pharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Specialty Pharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Specialty Pharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Specialty Pharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Specialty Pharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Specialty Pharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Specialty Pharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Specialty Pharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Specialty Pharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Specialty Pharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Specialty Pharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Specialty Pharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Specialty Pharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Specialty Pharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Specialty Pharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. South America Specialty Pharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Specialty Pharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Specialty Pharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Specialty Pharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Specialty Pharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. CVS Health Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Walgreens Boots Alliance, Inc.
  • 15.3. Express Scripts Holding Company
  • 15.4. UnitedHealth Group Incorporated
  • 15.5. Humana Inc.
  • 15.6. BioScrip, Inc.
  • 15.7. Diplomat Pharmacy, Inc.
  • 15.8. Accredo Health Group, Inc.
  • 15.9. Curant Health
  • 15.10. Avella Specialty Pharmacy

16. Strategic Recommendations

17. About Us & Disclaimer